News Search Results
Mar 27, 2026, 14:52 ET IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
e-mail at [email protected] ALLEGATIONS: ImmunityBio is a biotechnology company that focuses on innovating, developing, and commercializing next-generation immunotherapies. According to the complaint, ImmunityBio's
More news about: Robbins Geller Rudman & Dowd LLP
Mar 27, 2026, 10:01 ET Human Identification Market worth $1.69 billion by 2031 | MarketsandMarkets™
(US).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Mar 27, 2026, 09:15 ET Scalable Biotech Manufacturing Unlocks a $14B Market
portfolio. Both programs employ Austrianova's encapsulation technology.Avaí Bio recently completed a full rebrand and pivot into biotechnology, formerly operating as Avant Technologies. The company now concentrates on sourcing, developing, and protecting advanced cellular therapies
More news about: USA News Group
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 27, 2026, 08:36 ET Stratum Biosciences Secures $2M Seed Round to Accelerate AI-Powered Skin Biology Discovery and Expanded R&D Partnerships
NEW YORK, March 27, 2026 /PRNewswire/ -- Stratum Biosciences, a biotechnology pioneer at the intersection of artificial intelligence and dermatology research, announced the closing of a $2M seed funding round backed by the
More news about: Stratum Biosciences
Mar 27, 2026, 08:00 ET Otsuka Pharmaceutical to Acquire Transcend Therapeutics
related to assets in development, for a total potential consideration of USD $1.225 billion.Transcend, founded in 2021, is a clinical stage biotechnology company developing rapid-acting treatments for neuropsychiatric diseases. TSND-201 (methylone), which the company is developing, is a rapid-acting
More news about: Otsuka Pharmaceutical Co.; Transcend Therapeutics
Mar 27, 2026, 06:01 ET Global Agricultural Drones Market to Reach USD 23.1 Billion by 2032, Driven by Precision Farming and AI-Enabled Crop Intelligence | Vyansa Intelligence
Global Agricultural Biotechnology Market: The Global Agricultural Biotechnology Market is estimated at $ 126.35 Billion and is expected to grow to $ 275.84 Billion by 2032. Also, the market is projected
More news about: Vyansa Intelligence
Mar 27, 2026, 05:38 ET Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in
More news about: Biocon
Mar 26, 2026, 13:04 ET Locus FS Crowned 2026 Precision Fermentation Leader by Frost & Sullivan
innovation across diverse end markets."Through precision microbial design and high-performing glycolipid biosurfactants, Locus FS leverages biotechnology to develop biobased alternatives delivering real ROI. Its unified, platform-driven process accelerates the journey from concept to commercialization,
More news about: Locus FS
Mar 26, 2026, 10:08 ET Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million
2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia"), a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics
More news about: Insilico Medicine
Mar 26, 2026, 10:05 ET Household Insecticides Market to Reach US$ 31.7 Billion by 2033 Expands Amid Rising Health Concerns and Urban Living Trends - Persistence Market Research
2033Plant Biotechnology Services Market by Service Type (Genomics Services, Proteomics Services, Metabolomics Services, Analytical Chemistry, Cellular Imaging, Forage
More news about: Persistence Market Research Pvt. Ltd.
Mar 26, 2026, 10:00 ET High Throughput Screening Market to Reach USD 17,880 Million by 2031, Driven by Drug Discovery Advancements | Valuates Reports
micro-scale environments is reinforcing adoption across precision medicine and advanced therapeutic development initiatives.Pharmaceutical and Biotechnology Companies are central to the High Throughput Screening Market as they intensify compound library expansion, diversify therapeutic pipelines, and
More news about: Valuates Reports
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Pomerantz LLP
Mar 26, 2026, 09:00 ET Parker Institute for Cancer Immunotherapy Appoints Bolyn Hubby as Chief of Staff to Strengthen Organization Excellence During Period of Growth
infectious disease, immunology, and cancer immunotherapy. Previously, she served as Executive Vice President and Chief Corporate Affairs Officer at Vir Biotechnology, where she led government affairs, corporate communications, and public-private partnerships. Prior to Vir, she served as Chief Scientific Officer
More news about: Parker Institute for Cancer Immunotherapy
Mar 26, 2026, 09:00 ET SHINE and C-Ray Therapeutics Establish Strategic Partnership for Exclusive Distribution of Non-Carrier-Added Lu-177 in Mainland China
oncology's fastest-growing markets.Under the agreement, C-Ray will supply SHINE's n.c.a. Lu-177 to Chinese radiopharmaceutical developers, biotechnology companies, and healthcare institutions. Leveraging its integrated, 28,000-square-meter Chengdu facility, C-Ray will provide downstream services
More news about: SHINE Technologies, LLC
Mar 26, 2026, 08:53 ET C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China
C-Ray will serve as SHINE's exclusive distribution partner in mainland China, supplying n.c.a. Lu-177 to Chinese radiopharmaceutical developers, biotechnology companies, and healthcare institutions. C-Ray will leverage its integrated, 28,000-square-meter Chengdu facility to provide downstream services
More news about: C Ray Therapeutics
Mar 26, 2026, 08:31 ET MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2025, and provided a
More news about: MetaVia Inc.
Mar 26, 2026, 08:30 ET Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
Strategy Positions Hoth for Next Phase of GrowthWith the deployment of OpenClaw™, Hoth strengthens its positioning at the intersection of biotechnology and artificial intelligence—leveraging advanced analytics to drive innovation and pipeline expansion."We are entering a new phase of execution
More news about: Hoth Therapeutics, Inc.
Mar 26, 2026, 08:11 ET Global Times: China hosts multiple key forums, spotlighting co-op, opening-up, to inject stability in an uncertain world
forum for the first time, and he was already impressed by some of the technology advancement here in China."I'm very interested in AI and biotechnology where China already holds a leading edge in these fields, and I'm also looking to learn more about Chinese technology transfer opportunities for
More news about: Global Times
Mar 26, 2026, 08:00 ET Averna Therapeutics Announces Strategic Leadership Expansion
growthBOSTON, March 26, 2026 /PRNewswire/ -- Averna Therapeutics, Inc., a biotechnology company developing novel genomic medicines based on gene insertion technology, today announced the appointments of Robert Mabry, Ph.D., as Chief
More news about: Averna Therapeutics
Mar 26, 2026, 08:00 ET Braveheart Bio Appoints Emil deGoma, M.D., as Chief Medical Officer
SAN FRANCISCO, March 26, 2026 /PRNewswire/ -- Braveheart Bio, a clinical-stage biotechnology company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, today announced the
More news about: Braveheart Bio
Mar 26, 2026, 08:00 ET Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
mitochondrial therapeutics. He is supported by a team of experienced biotechnology executives, scientists and advisors with prior leadership roles at major pharmaceutical companies, academic medical centers and emerging biotechnology firms."We believe the focus in obesity will shift from
More news about: Pulmatrix Inc.
Mar 26, 2026, 07:30 ET Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics, Announces Oversubscribed $89 Million Series B Financing to Advance Pipeline into Clinical Trials
Pinnacle Medicines ("Pinnacle" or "the Company"), a biotechnology company pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, today announced the closing of
More news about: Pinnacle Medicines
Mar 26, 2026, 07:30 ET Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Mar 26, 2026, 06:00 ET Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
Calif., March 26, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced positive topline results in the GLOW2
More news about: Kodiak Sciences Inc.